Patent expirations won't hold back success of some drug firms

11/18/2003 | Bloomberg Businessweek

Although many drug firms are facing patent expirations next year, investors are bullish on several companies. For example, Pfizer is favored among investors based on anticipated 2004 sales of its recently approved drug for congestive heart failure. Abbott recently launched Humira, a rheumatoid arthritis drug that could be a hit, while Wyeth's lack of patent expirations could outweigh its weak pipeline.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY